Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors

Background China’s national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. Objective Under the Global Fund programmatic management of drug-resistant TB (2006–13), we assessed the attrition and delay in the pathway and the factors associated. Methods Cohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pre-treatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively. Results Of 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pre-treatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion ‘previously treated’ and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion ‘treatment after lost to follow up’. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion ‘recurrent TB’. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion ‘treatment after failure’. Conclusion The diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition.

[1]  B. Hedlund,et al.  Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection , 2018, Antimicrobial Agents and Chemotherapy.

[2]  H. Shewade,et al.  Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India. , 2018, Public health action.

[3]  H. Shewade,et al.  Provider reported barriers and solutions to improve testing among tuberculosis patients ‘eligible for drug susceptibility test’: A qualitative study from programmatic setting in India , 2018, PloS one.

[4]  Nyein Aye,et al.  Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar , 2018, PloS one.

[5]  John D Potter,et al.  Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations , 2018, PloS one.

[6]  Biao Xu,et al.  Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China , 2018, Antimicrobial Agents and Chemotherapy.

[7]  N. Ford,et al.  Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  Sanjay Singh Chahar,et al.  Treatment Initiation among Patients with Multidrug Resistant Tuberculosis in Bhopal District, India , 2017 .

[9]  D. Jeon WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea , 2017, Tuberculosis and respiratory diseases.

[10]  S. Swaminathan,et al.  Low pre-diagnosis attrition but high pre-treatment attrition among patients with MDR-TB: An operational research from Chennai, India , 2017, Journal of epidemiology and global health.

[11]  D. Falzon,et al.  The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership , 2017, PloS one.

[12]  Sanjay Singh Chahar,et al.  High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India , 2017, BMC Health Services Research.

[13]  F. Cobelens,et al.  Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study , 2017, PLoS medicine.

[14]  P. Memiah,et al.  Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies , 2017, Infectious Diseases of Poverty.

[15]  C. Palanivel,et al.  MDR-TB in Puducherry, India: reduction in attrition and turnaround time in the diagnosis and treatment pathway. , 2016, Public health action.

[16]  D. Moore,et al.  The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review , 2016, BMC Infectious Diseases.

[17]  H. Shewade,et al.  The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh , 2015, PloS one.

[18]  G. Roy,et al.  MDR-TB screening in a setting with molecular diagnostic techniques: who got tested, who didn't and why? , 2015, Public health action.

[19]  P. Curmi,et al.  Members of the Chloride Intracellular Ion Channel Protein Family Demonstrate Glutaredoxin-Like Enzymatic Activity , 2015, PloS one.

[20]  N. Pallewatte,et al.  Management of previously treated tuberculosis patients in Kalutara district, Sri Lanka: how are we faring? , 2014, Public health action.

[21]  Fei Huang,et al.  Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data , 2014, The Lancet.

[22]  Y. Li,et al.  Are We Doing Enough to Stem the Tide of Acquired MDR-TB in Countries with High TB Burden? Results of a Mixed Method Study in Chongqing, China , 2014, PloS one.

[23]  S. Egwaga,et al.  Are sputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. , 2013, Public health action.

[24]  S. Satyanarayana,et al.  Linkage of Presumptive Multidrug Resistant Tuberculosis (MDR-TB) Patients to Diagnostic and Treatment Services in Cambodia , 2013, PloS one.

[25]  S. Okada,et al.  The Identification of a Small Molecule Compound That Reduces HIV-1 Nef-Mediated Viral Infectivity Enhancement , 2011, PloS one.

[26]  A. Harries,et al.  Operational Challenges in Diagnosing Multi-Drug Resistant TB and Initiating Treatment in Andhra Pradesh, India , 2011, PloS one.

[27]  A. Harries,et al.  Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  C. Dolea,et al.  World Health Organization , 1949, International Organization.